SIAC hears claim over Russian covid vaccine partnership
Credit: Shutterstock/Juan Roballo
A Singapore biopharmaceutical company is pursuing a US$150 million SIAC claim against its Indian-owned partner over a collaboration to manufacture Russia’s Sputnik covid-19 vaccine.
To read more
Subscribe to Global Arbitration Review
Register for limited access
Register for free to receive GAR’s daily briefing and access to GAR 100.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now